Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637451 | 1.00 | ALDH1A1 (0.51) | ALDH1A1BCHEMAPTGAAPTPN2 | |
| SCHEMBL10157792 | 1.00 | ALDH1A1 (0.51) | ALDH1A1BCHEMAPTGAAPTPN2 | |
| SCHEMBL637450 | 1.00 | ALDH1A1 (0.51) | ALDH1A1BCHEMAPTGAAPTPN2 | |
| SCHEMBL636802 | 0.88 | MAPT (0.48) | ALDH1A1BCHEMAPTGAAPTPN2 | |
| SCHEMBL13574484 | 0.88 | MAPT (0.48) | ALDH1A1BCHEMAPTGAAPTPN2 | |
| SCHEMBL636803 | 0.88 | MAPT (0.48) | ALDH1A1BCHEMAPTGAAPTPN2 | |
| SCHEMBL12374904 | 0.87 | BCHE (0.44) | ALDH1A1BCHEMAPTGAAPTPN2 | |
| SCHEMBL10195517 | 0.86 | BCHE (0.44) | ALDH1A1BCHEGAAPTPN2PTPN1 | |
| SCHEMBL10194427 | 0.86 | BCHE (0.44) | ALDH1A1BCHEGAAPTPN2PTPN1 | |
| SCHEMBL638113 | 0.84 | CYP1A2 (0.46) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326652-B1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK SHARP & DOHME (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8119806-B2 | Cicletanine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119806-B2 | Cicletanine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029678-A1 | DIURETICS | NR3C2, REN, NR3C1 | ALDH1A1 2059/4885BCHE 2877/4885MAPT 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.